Kalray Unveils Coolidge™ at CES 2020
6.1.2020 20:00:00 EET | Business Wire | Press release
Kalray (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced the company will showcase its MPPA-3 aka Coolidge™, its third generation of unique and patented MPPA® (Massively Parallel Processor Array) processor family at CES 2020 in Las Vegas, from January 7 to 10, 2020.
COOLIDGE™ DEMONSTRATED AT CES
Just a few weeks after having received the first samples of Coolidge from manufacturing, Kalray will showcase a complete Artificial Intelligence use case running on Coolidge at CES, including a common demo with NXP, one of the leading semiconductor companies.
Coolidge samples general availability is planned for April.
COOLIDGE UNIQUELY POSITIONED FOR THE BOOMING MARKET OF INTELLIGENT SYSTEMS
Coolidge represents a 25X performance improvement (1) over second generation MPPA, with improvement of artificial intelligence capacities, increased ease of programming and higher-performance interfaces in particular for next generation of data centers.
Coolidge is targeting the booming market of intelligent systems, from next generation of data center infrastructure, 5G to next generation of cars. Coolidge is a compelling choice versus FPGA, which are expensive and difficult to program; GPU, which are tailored for mathematical algorithms; and AI processors, designed for AI only. Coolidge-based cards can be configured to deliver specialized acceleration performance in a wide set of demanding functions such as vision, signal processing, encryption, software stacks, real-time protocols, etc.
Eric Baissus, CEO of Kalray comments: “Yet another important phase for the company. Coolidge is the platform to support company's ambitions on data center markets, answering needs of growing diversity of Data Center workload acceleration and on automotive, enabling integration of multiple critical functions on the same chip while providing huge computing performance.”
DATA CENTER’S GROWING NEED FOR ACCELERATIONS AT COMPUTE, STORAGE AND NETWORKING
“2CRSi is eager to evaluate the new Coolidge processor from Kalray and excited to explore solutions leveraging Kalray’s configurable cards. The performance of this third-generation processor will enable an expansion of our offer in high-growth areas such as Artificial Intelligence or compute acceleration, while enabling more and more distributed and disaggregated data center implementations”, said Alain Wilmouth, CEO of 2CRSi.
AUTOMOTIVE AND EMBEDDED MARKETS NEED FOR INTEGRATION OF MULTIPLE CRITICAL FUNCTIONS AND HIGH COMPUTE PERFORMANCE
“We are very happy to see the strategic partnership with Kalray reach a new milestone and have Coolidge integrated into the NXP BlueBox, our development platform for automated driving, showcased at CES. We are convinced NXP and Kalray will bring multiple benefits to the development and industrialization of ADAS and AD vehicles with safe and secure solutions integrating multiple critical functions and providing very high computing performance” said Kamal Khouri, Vice President & General Manager, Advanced Driver Assistance, NXP.
Coolidge has been designed to address the challenges and constraints of the new generation of intelligent systems:
- High computing power with low energy consumption
- Open and easily programmable system
- Real-Time data processing and deterministic behavior
- Concurrent execution of many heterogeneous critical tasks in parallel on a single chip
- Advanced security and safety mechanisms suitable for the most demanding systems, defined in collaboration with Kalray’s partners in the aerospace, defense and automotive fields
For more information and to view the demonstrations, come and visit us at CES from January 7 to 10 at Las Vegas, USA: NXP’s booth #CP18, Central Plaza.
Next publication:
January 22, 2020: H2 2019 business report
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com
1 25 TOPS (Tera Operations Per Second) performance for Coolidge versus 1 TOPS for previous generation Bostan
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005664/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Caroline LESAGE
kalray@actus.fr
+
33 1 53 67 36 79
MEDIA CONTACTS
Loic HAMON
communication@kalray.eu
Tel.
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel.
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
